Supporting Somavert patients

Advice and support services to help you and your patients optimise your experience with Somavert

Somavert has a positive dose response, and dosing should be titrated to optimise IGF-I normalisation and improve symptoms1,2

Help find their personal optimum
Graphic to show how patients progress through dose strengths
The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response*1

Simplified proportion of patients achieving IGF-I control on each dose shown for illustrative purposes. *Maximum recommended dose of Somavert shold not exceed 30 mg/daily.

Discover how patients can incorporate daily self-administration into their routine
A Somavert patient demonstrates how the pre-filled diluent syringe enables straightforward reconstitution and administration at home

 

 

 

References

  1. Somavert Summary of Product Characteristics. July 2020. Available at https://www.medicines.org.uk/emc/medicine/14353 (last accessed August 2020).
  2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.

PP-SOM-GBR-0629. August 2020.

Starter kit contents are designed to help your patients feel confident with Somavert and self-administration

Image showing contents of treatment starter kit box

Each Somavert starter kit contains:

Patient information booklets
  • About Acromegaly
  • About Somavert, including the full user guide
Reconstitution guides
  • Preparing Somavert poster
  • USB stick with video guide
Practising tools
  • 3x Somavert demo packs (contains placebo)
  • Injection pad (for practising technique)
  • Injection site guide
Day-to-day injecting and ongoing support
  • Injection template for leg and abdomen
  • Box of swabs
  • Cool bag and instructions for use
  • Sharps bin
  • Helpline card

*Items are subject to change.

 

 

 

 

PP-SOM-GBR-0629. August 2020.

We offer a range of services that help your patients at home with medication delivery and face-to-face support 

Somavert delivery every four weeks Icon to indicate medication delivery to patients' homes
Standard homecare service: up to two home nurse visits Icon for nurse visits
Specialist homecare service: AcroCare Logo of specialist homecare service for people with acromegaly

 

Watch our guides on starting new patients according to each type of service

The patient journey with AcroCare
This animation explains how to start new Somavert patients using the AcroCare service

 

The patient journey with a standard homecare service
This animation explains how to start new Somavert patients using a standard homecare service

 

How AcroCare works

Specialist nurse support from day one
Comprehensive specialist nurse support from day one
Home visits to help patients feel confident with Somavert
  • Injection demonstration and training
  • Support with understanding their condition, why and how to get their treatment dose and frequency correct 
  • Help with storing Somavert appropriately
Named nurse phone calls to help keep them on track*
  • Check dosing and frequency is as prescribed
  • Help maintain understanding of their condition, treatment, dose and frequency 
  • Reminder of injection technique and helpline support

*Call volumes may vary by area and need.

 

 

 

PP-SOM-GBR-0629. August 2020.

Somavert has a positive dose response, allowing flexible dose titration to achieve IGF-I normalisation and improve symptoms1,2

IGF-I normalisation rates with increasing dose strengths
Graph showing dose response
Percentage of Somavert patients achieving IGF-I normalisation after 12 weeks of treatment2

*p=0.02. **p<0.001.

 

Somavert is a daily subcutaneous injection available in five vial sizes of 10 mg, 15 mg, 20 mg, 25 mg and 30 mg

The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response1

Image showing five vial dose strengths of treatment and pre-filled syringe

  • Any daily dose can be self-administered with a single injection1
  • No need for patients to visit a clinic
  • No time or food restrictions
  • Pre-filled diluent syringe with enlarged finger grip and plunger for convenience
  • NB powder vials must should be stored in the fridge. However, they may be stored at room temperature up to a maximum of 25°C for a single period of up to 30 days.†
  • Diluent syringe can be kept out of the fridge (<30°C) prior to reconstitution

†Please refer to the Summary of Product Characteristics for the full information about storage.

 

 

 

References

  1. Somavert Summary of Product Characteristics. July 2020. Available at: https://www.medicines.org.uk/emc/product/64/smpc (last accessed August2020).
  2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.

PP-SOM-GBR-0629. August 2020.

Patients receiving homecare services will have their own dedicated, nurse-led helpline to support with patient enquiries

All patients with either standard or the enhanced AcroCare homecare services will be given their own dedicated helpline number to call

A freephone Pfizer Endocrine Helpline service is also available to clinicians and patients on 0800 521249

Email: [email protected]

Opening hours

Monday - Thursday: 9am - 5pm

Friday only: 9am - 4pm

(Answer phone available out of hours)
 

The Pfizer Endocrine Helpline team of nurses provides direct support for patients not receiving homecare services

Image of Pfizer Endocrine Helpline team

We typically handle any queries relating to medication and supplies deliveries, reconstitution and self-administration advice.

 

PP-SOM-GBR-0629. August 2020.

Pfizer Home

Clinical Information

Prescribing Somavert®

Find information on funding, initiation, homecare and follow-up

Image of acromegaly patient and HCP guide to prescribing treatment
Download the guide >
Order more starter kits >

Image showing contents of treatment starter kit box
Prescribing Somavert® for patients with no homecare

This animation explains how to set up new Somavert® patients where no homecare is available or the patient chooses not to receive it
Enquire about Homecare in your area >
Learn about the pharmacist's role in Homecare

Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and BlueTeq funding arrangements to homecare service provision
Discover the full series of Acromegaly Expert Webinars >